, Volume 120, Issue 1, pp 235-244
Date: 13 Aug 2009

Physical activity and the risk of breast cancer in BRCA1/2 mutation carriers

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

BRCA1/2 mutation carriers have a high lifetime risk of developing breast cancer. Differences in penetrance indicate that this risk may be influenced by lifestyle factors. Because physical activity is one of the few modifiable risk factors, it may provide a target to add to breast cancer prevention in this high-risk population. We examined the association between self-reported lifetime sports activity and breast cancer risk in a nationwide retrospective cohort study, including 725 carriers, of whom 218 had been diagnosed with breast cancer within 10 years prior to questionnaire completion. We found a nonsignificantly decreased risk for ever engaging in sports activity (HR = 0.84, 95%CI = 0.57–1.24). Among women who had participated in sports, a medium versus low level of intensity and duration (i.e., between 11.0 and 22.7 mean MET hours/week averaged over a lifetime) reduced the risk of breast cancer (HR = 0.59, 95%CI = 0.36–0.95); no dose–response trend was observed. For mean hours/week of sports activity, a nonsignificant trend was observed (HRlow versus never = 0.93, 95%CI = 0.60–1.43; HRmedium versus never = 0.81, 95%CI = 0.51–1.29; HRhigh versus never = 0.78, 95%CI = 0.48–1.29; p trend overall = 0.272; p trend active women = 0.487). For number of years of sports activity no significant associations were found. Among women active in sports before age 30, mean MET hours/week showed the strongest inverse association of all activity measures (HRmedium versus low = 0.60, 95%CI = 0.38–0.96; HRhigh versus low = 0.58, 95%CI = 0.35–0.94; p trend = 0.053). Engaging in sports activity after age 30 was also inversely associated with breast cancer risk (HR = 0.63, 95%CI = 0.44–0.91). Our results indicate that sports activity may reduce the risk of breast cancer in BRCA1/2 mutation carriers.

The Netherlands Collaborative Group on Hereditary Breast Cancer (HEBON) is given in Appendix.